Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank44
Year-over-Year Change
Year-over-year SG&A expense growth
Latest
1.02%
↓ 89% vs avg
Percentile
P44
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
9.22%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 1.02% |
| Q3 2025 | -0.38% |
| Q2 2025 | 34.74% |
| Q1 2025 | -18.75% |
| Q4 2024 | 33.64% |
| Q3 2024 | -11.03% |
| Q2 2024 | 17.84% |
| Q1 2024 | 6.40% |
| Q4 2023 | -0.53% |
| Q3 2023 | -7.23% |
| Q2 2023 | 16.90% |
| Q1 2023 | -12.69% |
| Q4 2022 | -10.82% |
| Q3 2022 | 38.75% |
| Q2 2022 | 10.04% |
| Q1 2022 | -17.12% |
| Q4 2021 | 31.19% |
| Q3 2021 | -2.24% |
| Q2 2021 | -1.05% |
| Q1 2021 | -11.69% |
| Q4 2020 | -0.71% |
| Q3 2020 | 30.94% |
| Q2 2020 | 0.90% |
| Q1 2020 | -18.89% |
| Q4 2019 | 29.85% |
| Q3 2019 | 6.72% |
| Q2 2019 | 25.85% |
| Q1 2019 | -17.55% |
| Q4 2018 | -6.74% |
| Q3 2018 | 37.63% |
| Q2 2018 | 16.88% |
| Q1 2018 | 7.40% |
| Q4 2017 | 41.58% |
| Q3 2017 | 4.07% |
| Q2 2017 | 18.95% |
| Q1 2017 | 38.07% |
| Q4 2016 | 24.50% |
| Q3 2016 | 24.48% |
| Q2 2016 | -14.75% |
| Q1 2016 | 22.48% |